SGYP Share Price

Open 4.55 Change Price %
High 4.86 1 Day 0.21 4.60
Low 4.50 1 Week 0.13 2.80
Close 4.78 1 Month -1.01 -17.44
Volume 10608199 1 Year 2.11 79.03
52 Week High 7.15
52 Week Low 2.60
SGYP Important Levels
Resistance 2 5.11
Resistance 1 4.98
Pivot 4.71
Support 1 4.58
Support 2 4.45
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
MU 28.76 1.16%
MU 28.76 1.16%
MU 28.76 1.16%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
IPXL 12.70 37.30%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
RGLS 1.70 21.43%
SCON 1.54 19.38%
CPRX 2.01 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP)

SGYP Technical Analysis 4
As on 27th Mar 2017 SGYP Share Price closed @ 4.78 and we RECOMMEND Sell for LONG-TERM with Stoploss of 4.87 & Strong Sell for SHORT-TERM with Stoploss of 5.84 we also expect STOCK to react on Following IMPORTANT LEVELS.
SGYP Target for March
1st Target up-side 6.54
2nd Target up-side 7.07
3rd Target up-side 7.6
1st Target down-side 5.04
2nd Target down-side 4.51
3rd Target down-side 3.98
SGYP Other Details
Segment EQ
Market Capital 240850608.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.synergypharma.com
SGYP Address
SGYP
420 Lexington Avenue
Suite 2012
New York, NY 10170
United States
Phone: 212-297-0020
Fax: 212-297-0019
SGYP Latest News
Interactive Technical Analysis Chart Synergy Pharmaceuticals, Inc. ( SGYP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Synergy Pharmaceuticals, Inc.
SGYP Business Profile
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company�s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis (UC). The Company�s active pharmaceutical ingredients (APIs) and the final formulated drug products are manufactured for it by third party contractors. As of December 31, 2011, the Company was developing plecanatide, a synthetic hexadecapeptide designed to mimic the actions of the GI hormone uroguanylin, for the treatment of CC and IBS-C. Plecanatide is an agonist of GC-C receptor.